Bayer strengthens top end of haematology analysers range
This article was originally published in Clinica
Bayer plans to launch its new haematology system, Advia 120, throughout the world in September. The German company hopes to obtain US FDA approval within the next few months. The new analyser addresses the top end of the market, an area where Bayer is already strong.
You may also be interested in...
The Swiss giant is hoping to get seven more approvals for its blockbuster immunology drug over the next 10 years.
Cadila has filed for approval of saroglitazar for NASH in India. The drug, which could emerge as the first medicine for the indication if approved, is already being used by a million Indian patients for diabetic dyslipidemia and hypertriglyceridemia.
It has been a long and sometimes tortuous development path for Lupuzor but ImmuPharma's chief executive tells Scrip the company's faith in the lupus drug is bearing fruit.